Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis

Ying Ting Sit, Kaoru Takasaki, Hyun Hyung An, Xiao Yan, Christian Hurtz, Peter A. Gearhart, Zhe Zhang, Paul Gadue, Deborah L. French, Stella T. ChouJCI 2023 · DOI

TL;DR

This study investigates how the gene DYRK1A, overexpressed in Down syndrome (DS)-associated leukemia, interacts with the mutated GATA1s protein in human stem cells. Surprisingly, losing DYRK1A in the presence of GATA1s increases the proliferation of immature megakaryocytes, suggesting DYRK1A might actually act as a brake on leukemia development in certain contexts.

What Problem Does This Paper Address?

Children with Down syndrome (DS), or trisomy 21 (T21), have a significantly higher risk of developing transient abnormal myelopoiesis (TAM) and acute megakaryoblastic leukemia (ML-DS). These conditions are linked to a specific truncated version of the GATA1 gene, called GATA1s, which arises from a mutation. While it's known that having an extra copy of chromosome 21 (T21) and the GATA1s mutation are both necessary for leukemia development, the precise mechanisms by which other genes on chromosome 21, like DYRK1A, contribute to this process are not well understood. DYRK1A is known to be overexpressed in ML-DS, making it a potential therapeutic target. However, the authors wanted to understand how DYRK1A's function, particularly in conjunction with GATA1s, impacts megakaryocyte development in human cells, as previous studies in mice haven't fully recapitulated human disease.

Methods

The researchers utilized a sophisticated approach involving gene editing and human induced pluripotent stem cells (iPSCs). They generated isogenic T21 iPSC lines that either had the normal GATA1 (wtGATA1) or the mutated GATA1s. Using CRISPR/Cas9 gene editing, they then knocked out all three alleles of the DYRK1A gene in these lines. These modified iPSCs were then differentiated into hematopoietic progenitor cells and subsequently into megakaryocytes. Various techniques were employed to analyze these cells, including:

  • Western blotting: To confirm the knockout of DYRK1A and assess protein levels of cell cycle regulators.
  • Flow cytometry: To analyze cell surface markers (like CD41, CD42b, CD43, CD235) and cell cycle status (EdU incorporation for S-phase, Ki67 for proliferation, Annexin V for apoptosis).
  • Liquid cultures: To assess the expansion and differentiation potential of progenitor cells into megakaryocytes, myeloid, and erythroid lineages.
  • Colony-forming assays: To evaluate the lineage bias of progenitor cells.
  • RNA sequencing (RNA-seq): To globally analyze gene expression changes in progenitors and megakaryocytes.
  • Gene Set Enrichment Analysis (GSEA): To identify enriched biological pathways in the RNA-seq data.
  • Functional assays: Such as PAC-1 binding to assess megakaryocyte activation.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • DYRK1A's role is context-dependent: The most striking finding is that DYRK1A's effect on megakaryopoiesis is heavily influenced by the GATA1 status. Loss of DYRK1A had no significant impact on megakaryocytes with normal GATA1, but it dramatically altered the behavior of cells with the mutated GATA1s.
  • DYRK1A as a "brake" on proliferation: Contrary to the expectation that overexpressed DYRK1A might drive leukemia, the study suggests that DYRK1A, in conjunction with wtGATA1, acts to restrain megakaryocyte proliferation. Its loss, in the presence of GATA1s, removes this restraint, leading to uncontrolled proliferation.
  • Synergistic control of cell cycle: The findings point to a coordinated effort between wtGATA1 and DYRK1A to regulate the cell cycle and promote megakaryocyte maturation. The mutated GATA1s disrupts this control, and the absence of DYRK1A exacerbates the problem.
  • Implications for therapeutic targeting: The unexpected role of DYRK1A as a potential suppressor of GATA1s-driven proliferation suggests that simply inhibiting DYRK1A might not be a viable therapeutic strategy for ML-DS and could even be detrimental.

Key Results

  • DYRK1A is overexpressed in T21 cells: Consistent with previous findings, DYRK1A levels were higher in T21 cells, particularly in megakaryocytes carrying the GATA1s mutation.
  • DYRK1A loss enhances proliferation in T21/GATA1s cells: Knocking out DYRK1A in T21 iPSCs with GATA1s led to increased proliferation of megakaryocyte and myeloid progenitors. This was further evidenced by increased EdU and Ki67 incorporation in T21/GATA1s/DYRK1A-/-/- megakaryocytes.
  • DYRK1A loss impairs maturation: The loss of DYRK1A in T21/GATA1s megakaryocytes was associated with decreased expression of maturation markers (CD41, CD42b MFI) and impaired activation (reduced PAC-1 binding), indicating an immature phenotype.
  • Cell cycle machinery is dysregulated: RNA-seq and protein analysis revealed that DYRK1A loss in T21/GATA1s cells led to the upregulation of D-type cyclins, hyperphosphorylation of Rb, and increased expression of E2F target genes, all hallmarks of uncontrolled cell cycle progression.
  • Species-specific effects: The study highlights a divergence from murine models, where DYRK1A overexpression has been shown to promote megakaryopoiesis. In human cells, DYRK1A appears to restrain it.

Limitations and Future Work

  • Early hematopoiesis model: The study uses iPSCs differentiated into early hematopoietic progenitors, which primarily recapitulate yolk sac hematopoiesis. TAM and ML-DS arise in later fetal and postnatal stages. While this model provides valuable insights, it may not fully capture all aspects of disease development.
  • In vitro vs. in vivo: The findings are based on in vitro studies. Further in vivo validation would be necessary to confirm these observations in a more complex biological system.
  • Therapeutic implications: The authors suggest that DYRK1A inhibition might not be a therapeutic option for GATA1s-associated leukemias, implying that alternative therapeutic strategies targeting other pathways are needed. Future work could focus on identifying these alternative targets or exploring how to modulate DYRK1A activity in a more nuanced way.
  • Further investigation of DREAM complex: The study points to DYRK1A's role in the DREAM complex. Further research could delve deeper into how DYRK1A's interaction with this complex specifically impacts megakaryocyte cell cycle control in the context of T21 and GATA1s.

Summary updated

Abstract

Patients with Down syndrome (DS), or trisomy 21 (T21), are at increased risk of transient abnormal myelopoiesis (TAM) and acute megakaryoblastic leukemia (ML-DS). Both TAM and ML-DS require prenatal somatic mutations in GATA1, resulting in the truncated isoform GATA1s. The mechanism by which individual chromosome 21 (HSA21) genes synergize with GATA1s for leukemic transformation is challenging to study, in part due to limited human cell models with wild-type GATA1 (wtGATA1) or GATA1s. HSA21-encoded DYRK1A is overexpressed in ML-DS and may be a therapeutic target. To determine how DYRK1A influences hematopoiesis in concert with GATA1s, we used gene editing to disrupt all 3 alleles of DYRK1A in isogenic T21 induced pluripotent stem cells (iPSCs) with and without the GATA1s mutation. Unexpectedly, hematopoietic differentiation revealed that DYRK1A loss combined with GATA1s leads to increased megakaryocyte proliferation and decreased maturation. This proliferative phenotype was associated with upregulation of D-type cyclins and hyperphosphorylation of Rb to allow E2F release and derepression of its downstream targets. Notably, DYRK1A loss had no effect in T21 iPSCs or megakaryocytes with wtGATA1. These surprising results suggest that DYRK1A and GATA1 may synergistically restrain megakaryocyte proliferation in T21 and that DYRK1A inhibition may not be a therapeutic option for GATA1s-associated leukemias.
BibTeX
@inproceedings{sit2023synergistic,
  author = {Ying Ting Sit and Kaoru Takasaki and Hyun Hyung An and Xiao Yan and Christian Hurtz and Peter A. Gearhart and Zhe Zhang and Paul Gadue and Deborah L. French and Stella T. Chou},
  title = {{Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis}},
  booktitle = {JCI},
  year = {2023},
  doi = {10.1172/jci.insight.172851},
}
Figure